Introduction：Basic information about CAS 5011-34-7|Trimetazidine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Trimetazidine |
|---|
| CAS Number | 5011-34-7 | Molecular Weight | 274.385 |
|---|
| Density | 1.1±0.1 g/cm3 | Boiling Point | 364.0±37.0 °C at 760 mmHg |
|---|
| Molecular Formula | C14H22N2O3 | Melting Point | 200 - 205ºC |
|---|
| MSDS | / | Flash Point | 174.0±26.5 °C |
|---|
Names
| Name | 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine |
|---|
| Synonym | More Synonyms |
|---|
Trimetazidine BiologicalActivity
| Description | Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4]. |
|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Autophagy >>Autophagy |
|---|
| Target | IC50: 75 nM (long chain 3-ketoyl coenzyme A thiolase)[2] β-oxidation[2] Autophagy[3] 3-hydroxyacyl-CoA dehydrogenase (HADHA)[4] |
|---|
| In Vitro | Trimetazidine (1-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induced by oxidation in a certain dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: Human umbilical vein endothelial cells (HUVECs) Concentration: 1 μM,10 μM,100 μM Incubation Time: 24 hours Result: Enhanced the viability of the injured HUVECs induced by oxidation. |
|---|
| In Vivo | Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 and 20mg/kg doses significantly raises the seizure-threshold current in the ICES test in the mice[5]. Animal Model: Swiss albino male mice (24-35 g)[4] Dosage: 5 mg/kg, 10 mg/kg and 20 mg/kg; 10 mL/kg body weight Administration: Oral administration ; 1 hour Result: In 10 and 20mg/kg doses significantly raised the seizure-threshold current in the ICES test. |
|---|
| References | [1]. Shenghu He, et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation. Journal of Geriatric Cardiology, December 2008 , Vol 5 No 4. [2]. Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74(9):971-80. [3]. Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8. [4]. Hossain F, et al.Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015 Nov;3(11):1236-47. [5]. Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19(5):300-2. |
|---|
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|
| Boiling Point | 364.0±37.0 °C at 760 mmHg |
|---|
| Melting Point | 200 - 205ºC |
|---|
| Molecular Formula | C14H22N2O3 |
|---|
| Molecular Weight | 274.385 |
|---|
| Flash Point | 174.0±26.5 °C |
|---|
| Exact Mass | 274.213257 |
|---|
| PSA | 42.96000 |
|---|
| LogP | 0.80 |
|---|
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.524 |
|---|
| InChIKey | UHWVSEOVJBQKBE-UHFFFAOYSA-N |
|---|
| SMILES | COc1ccc(CN2CCNCC2)c(OC)c1OC |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| HS Code | 2933599090 |
|---|
Customs
| HS Code | 2933599090 |
|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| Piperazine-2,2,3,3,5,5,6,6-d, 1-[(2,3,4-trimethoxyphenyl)methyl]- |
| Trimetazidine HCl |
| EINECS 225-690-2 |
| MFCD00868263 |
| Trimetazidine |
| 1-(2,3,4-Trimethoxybenzyl)(2,2,3,3,5,5,6,6-H)piperazine |
